Antengene
Mr. Karalis has over 30 years of experience in the pharmaceutical industry, including as the former General Manager for Celgene East Asia and Vice President & General Manager for Celgene Australia and New Zealand.
During Mr. Karalis’ tenure at Celgene, multiple regulatory and reimbursement milestones were achieved for core products in APAC markets leading to successful launches of REVLIMID® (lenalidomide), POMALYST® (pomalidomide), and ABRAXANE® (paclitaxel protein-bound particles for injectable suspension).
This person is not in any offices